Previous 10 | Next 10 |
BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application (CTA) by th...
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene a...
2023-03-30 08:33:19 ET The European Commission (EC) granted orphan drug designation to Decibel Therapeutics' ( NASDAQ: DBTX ) gene therapy DB-OTO to treat profound, congenital hearing loss caused by mutations of the otoferlin gene. The European Medicines Agency's...
- Decibel intends to initiate a Phase 1/2 clinical trial of DB-OTO in patients with congenital hearing loss caused my mutations of the otoferlin gene in the first half of 2023 - - There are currently no approved pharmacologic treatment options for individuals with otoferlin-related hearin...
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, ...
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of D...
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, w...
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery...
Decibel Therapeutics ( NASDAQ: DBTX ) said its clinical trial application (CTA) received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for starting a phase 1/2 trial in children of gene therapy DB-OTO. DB-OTO, which is being developed in coll...
The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger One-time administration of DB-OTO has resulted in production of otoferlin protein and durable auditory brainstem responses...
News, Short Squeeze, Breakout and More Instantly...
Decibel Therapeutics Inc. Company Name:
DBTX Stock Symbol:
NASDAQ Market:
Decibel Therapeutics Inc. Website:
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Decibel Therapeutics Inc. (DBTX) is expected to report $-0.61 for Q3 2023
NEW YORK, NY / ACCESSWIRE / August 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:A Decibel Therapeutics, Inc. (NASDAQ...